Jun 06, 2020
AbbVie Presents Data Showing RINVOQ(TM) (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients
Feb 04, 2019
Global Rheumatoid Arthritis Competitor Landscape Report 2018-2019YE
Dec 20, 2018
AbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis
Dec 18, 2018
Global Vitiligo Market Research Report 2018-2024 Featuring AXIM Biotechnologies, Boston Pharma, Bristol-Myers Squibb, Castle Creek Pharma,Clinuvel Pharma, Dermavant Sciences, Incyte & JN Biosciences
Dec 09, 2017
Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant
Nov 21, 2017
Recent Chart Audit Reveals Switching Rheumatoid Arthritis Patients to Roche/Genentech's RoActemra (Actemra) is Significantly More Common in the EU5 than it is in the US
Oct 20, 2017
US Rheumatologists Teed Up for Rapid Adoption of BMS' Orencia in Psoriatic Arthritis, Though the Real Game Changer Could Come with the Approval of Pfizer's Xeljanz
Oct 16, 2017
Despite Rheumatologist Reports that BMS' Orencia is Their Preferred Non-TNF Agent for Treating Rheumatoid Arthritis, Pfizer's Xeljanz Provides Steep Competition in Actual Switching Patterns
Sep 26, 2017
Analysis of Over 1000 Psoriatic Arthritis (PsA) Patients Reveals Large Candidate Pool for Pfizer's Xeljanz, BMS' Orencia, and Eli Lilly's Taltz